Comparative thromboembolic risk in atrial fibrillation patients with and without a concurrent infection

[1]  Ulrich Schotten,et al.  2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS. , 2017, Revista espanola de cardiologia.

[2]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.

[3]  Peter A Noseworthy,et al.  Typical, atypical, and asymptomatic presentations of new-onset atrial fibrillation in the community: Characteristics and prognostic implications. , 2016, Heart rhythm.

[4]  G. Lip,et al.  Stroke prevention in atrial fibrillation: a systematic review. , 2015, JAMA.

[5]  D. Levy,et al.  Long-Term Outcomes of Secondary Atrial Fibrillation in the Community The Framingham Heart Study , 2015 .

[6]  M. Ezekowitz,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. , 2014, Circulation.

[7]  M. Ezekowitz,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. , 2014, Circulation.

[8]  E. Benjamin,et al.  Long-term outcomes following development of new-onset atrial fibrillation during sepsis. , 2014, Chest.

[9]  J. Healey,et al.  Perioperative atrial fibrillation and the long-term risk of ischemic stroke. , 2014, JAMA.

[10]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[11]  K. Overvad,et al.  Validity of the diagnoses atrial fibrillation and atrial flutter in a Danish patient registry , 2012, Scandinavian cardiovascular journal : SCJ.

[12]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[13]  J. Hallas,et al.  The Danish National Prescription Registry , 2011, Scandinavian journal of public health.

[14]  C. Pedersen,et al.  The Danish Civil Registration System , 2011, Scandinavian journal of public health.

[15]  Elsebeth Lynge,et al.  The Danish National Patient Register , 2011, Scandinavian journal of public health.

[16]  K. Helweg-larsen.  The Danish Register of Causes of Death , 2011, Scandinavian journal of public health.

[17]  Silvia G Priori,et al.  2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2011, Circulation.

[18]  Jun Zhu,et al.  Apixaban in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[19]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[20]  T. Truelsen,et al.  Validity of Stroke Diagnoses in a National Register of Patients , 2007, Neuroepidemiology.

[21]  Bernard Rosner,et al.  The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. , 1990, The New England journal of medicine.

[22]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .